A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself.
After receiving "unsolicited" buyout proposals from Michigan-based CDMO Future Pak and U.K. drugmaker Cycle Pharmaceuticals, Vanda's board concluded that both offers "substantially undervalue" the company. Vanda has rejected the proposals, the company said in a June 19 press release.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,